News & Updates

Show Multimedia Only

Long-term bulevirtide use safe, efficacious in chronic HDV

29 Sep 2024 by

Longer treatment with bulevirtide (BLV) monotherapy in patients with chronic hepatitis delta (CHD) for 96 weeks results in sustained or continued improvements in virologic, biochemical, and combined responses, a study has shown.

Long-term bulevirtide use safe, efficacious in chronic HDV

29 Sep 2024

Monthly erenumab jabs promising for chronic migraine, medication overuse headaches

28 Sep 2024 by

Monthly injections of erenumab help induce and sustain remission of chronic migraine and medication overuse headaches, as shown in the phase IV INOVA study.

Monthly erenumab jabs promising for chronic migraine, medication overuse headaches

28 Sep 2024

Sintilimab plus bevacizumab shows therapeutic potential in ovarian clear cell carcinoma

27 Sep 2024

In the treatment of patients with relapsed or persistent ovarian clear cell carcinoma, the combination of sintilimab plus bevacizumab has demonstrated promising antitumour activity and manageable safety in the phase II INOVA trial.

Sintilimab plus bevacizumab shows therapeutic potential in ovarian clear cell carcinoma

27 Sep 2024

COVID-19 vaccine acceptance low among mothers in SG

26 Sep 2024 by

Pregnant and lactating women in Singapore generally have low acceptance of the COVID-19 vaccine due to safety concerns, reports a recent study.

COVID-19 vaccine acceptance low among mothers in SG

26 Sep 2024

$Nanvuranlat confers PFS gains in advanced, refractory biliary tract cancer$

Nanvuranlat confers PFS gains in advanced, refractory biliary tract cancer

26 Sep 2024

The investigational L-type amino acid transporter 1 inhibitor nanvuranlat has an acceptable safety profile and is associated with prolonged progression-free survival (PFS) in patients with advanced and refractory biliary tract cancer when used in later-line treatment settings, according to the results of a phase II study.

Nanvuranlat confers PFS gains in advanced, refractory biliary tract cancer

26 Sep 2024

Pitavastatin may increase new-onset diabetes risk

26 Sep 2024 by

In a comparative analysis presented at WONCA 2024, individuals who are being treated with pitavastatin appear to be at greater risk of developing new-onset diabetes as opposed to those receiving rosuvastatin.

Pitavastatin may increase new-onset diabetes risk

26 Sep 2024

Tamsulosin offers no advantage for postoperative voiding, discharge in hysterectomy patients

25 Sep 2024

Treatment with a single dose of tamsulosin prior to minimally invasive hysterectomy for benign conditions does not shorten postoperative time to void or time to discharge, as reported in a study.

Tamsulosin offers no advantage for postoperative voiding, discharge in hysterectomy patients

25 Sep 2024

Novel PCSK9 inhibitor helps achieve LDL-C targets in high-risk patients on statins

25 Sep 2024 by

Monthly dosing of the anti-PCSK9 small binding protein lerodalcibep appears to significantly reduce low-density lipoprotein cholesterol (LDL-C) in patients with cardiovascular disease (CVD) or at high risk of atherosclerotic CVD who are unable to achieve target LDL-C levels while receiving maximal tolerated statins alone, according to the phase III LIBERATE-HR trial.

Novel PCSK9 inhibitor helps achieve LDL-C targets in high-risk patients on statins

25 Sep 2024

Early antibiotic exposure tied to immune-mediated diseases in children, young adults

25 Sep 2024 by

A registry-based cohort study presented at ERS 2024 demonstrates a relationship between antibiotic exposure in early life and the development of immune-mediated diseases (IMDs) in childhood and young adulthood.

Early antibiotic exposure tied to immune-mediated diseases in children, young adults

25 Sep 2024

Medical cannabinoids come with risks for paediatric use

25 Sep 2024

Cannabinoids for medical purposes in children and adolescents have been linked to increased risk of adverse events (AEs), according to the results of a meta-analysis.

Medical cannabinoids come with risks for paediatric use

25 Sep 2024

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Long-term bulevirtide use safe, efficacious in chronic HDV

Long-term bulevirtide use safe, efficacious in chronic HDV

Monthly erenumab jabs promising for chronic migraine, medication overuse headaches

Monthly erenumab jabs promising for chronic migraine, medication overuse headaches

Sintilimab plus bevacizumab shows therapeutic potential in ovarian clear cell carcinoma

Sintilimab plus bevacizumab shows therapeutic potential in ovarian clear cell carcinoma

COVID-19 vaccine acceptance low among mothers in SG

COVID-19 vaccine acceptance low among mothers in SG

Nanvuranlat confers PFS gains in advanced, refractory biliary tract cancer

Nanvuranlat confers PFS gains in advanced, refractory biliary tract cancer

Pitavastatin may increase new-onset diabetes risk

Pitavastatin may increase new-onset diabetes risk

Tamsulosin offers no advantage for postoperative voiding, discharge in hysterectomy patients

Tamsulosin offers no advantage for postoperative voiding, discharge in hysterectomy patients

Novel PCSK9 inhibitor helps achieve LDL-C targets in high-risk patients on statins

Novel PCSK9 inhibitor helps achieve LDL-C targets in high-risk patients on statins

Early antibiotic exposure tied to immune-mediated diseases in children, young adults

Early antibiotic exposure tied to immune-mediated diseases in children, young adults

Medical cannabinoids come with risks for paediatric use

Medical cannabinoids come with risks for paediatric use